EUCTR2004-004139-74-DK
Active, Not Recruiting
Phase 1
Parkinson’s Disease: PET scan and evaluation of memantines pharmacological effect.(Parkinsons sygdom bedømt med PET skanning, herunder memantins farmakologiske effekt.) - N/A
eurologisk afdeling F0 sites12 target enrollmentMarch 22, 2005
DrugsEbixa
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- eurologisk afdeling F
- Enrollment
- 12
- Status
- Active, Not Recruiting
- Last Updated
- 9 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Idiopathic Parkinson's Disease (ICD\-10: G20\.9\)
- •2\) Age 50\-70
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •1\) Any current use of tobacco substances containing nicotine.
- •2\) Conditions prohibiting MR scan (implanted pacemaker, protheses etc.)
- •3\) Brain diseases apart from Parkinson's Disease (Aneurisms, AV\-malformations, stroke, cranial trauma, dementia etc.)
- •4\) Psychiatric disorders (Schizophrenia, bi\-polar mood disorder, depression)
- •5\) Other major diseases (heartfailure, arhytmias, infarcts, kidney failure, liver failure, cirrhosis, active hepatitis, portal hypertension etc.)
- •6\) Current use of drugs with major influence on CNS (eg. amphetamine, metamphetamine, cocaine, opioids, antipsychotics, antiepileptics, NMDA\-antagonists)
- •7\) Current use of the anti\-parkinsonian drugs Cabergolin and Amantadine.
- •8\) Pregnancy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
Profiling Parkinson’s diseaseParkinson's diseaseNL-OMON21445Amsterdam UMC, location VUmc1,515
Withdrawn
N/A
The role of imaging in Parkinson*s disease subtypes: a pilot study .NL-OMON35081eids Universitair Medisch Centrum10
Unknown
N/A
Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic CharacteristicsParkinson DiseaseNCT01089283Tel-Aviv Sourasky Medical Center80
Recruiting
N/A
Profiling Parkinson's diseaseNL-OMON54513Vrije Universiteit Medisch Centrum1,515
Completed
N/A
Establishing 18F PMPBB3 (APN 1607) PET Imaging Markers for Diagnosis of Tauopathy Parkinsonism SyndromesTau Distributions in Patients With Tauopathy Using APN-1607 PET ScanNCT04557865National Taiwan University Hospital68